Earnings Releases·Nov 13, 2026, 4:47 PM ET

Femasys Inc. — Q3 2026 Earnings Summary

Total sales for the quarter ended September 30, 2026, declined 44.5% year-over-year to $404,597, while net loss narrowed to $4.56 million ($0.53 per share) from $4.19 million ($2.05 per share) in the prior year period.
The company closed a $30 million private placement in mid-August 2026, increasing cash and cash equivalents to $23.9 million and reducing total liabilities to $8.06 million.
FemBloc received FDA approval for its modular premarket approval submission approach, with the number of enrolling sites in the FINALE pivotal trial doubling to twelve.
Management anticipates revenue growth following the deployment of a newly built commercial team and expects distributor reorders for FemBloc once post-market studies are completed.
FemaSeed Fertility Portfolio secured new partnerships with UNC Health, Minnesota Women's Care, CapexMD, and SandsRx to expand OB/GYN practice adoption and patient financing.